Clinical Overview of Cannabigerol
Alpha-2 adrenergic receptor agonist, 5-HT1A serotonin antagonist, moderate CB1/CB2 antagonist
Key Action
Intestinal micro-relief, ocular nerve defense, and neurogenesis motivation.
Clinical Abstract
Cannabigerol (CBG) is hailed as the 'Mother of Cannabinoids' because its acidic form (CBGA) is the chemical precursor from which all other major compounds are synthesized. Structurally unique, CBG displays high affinity for alpha-2 adrenergic receptors and acts as a moderate blocker of serotonin pathways. It has shown remarkable efficacy in the gastrointestinal tract, where CB2 and adrenergic receptors are heavily integrated. CBG reduces inflammatory gene expression, eases bowel spasticity, and possesses robust antibacterial properties against drug-resistant pathogens. Furthermore, CBG stimulates neural growth factor, promoting neurogenesis.
Physiological Mechanisms of Action
Target Clinical Indications
Dosing & Titration Protocols (“Start Low and Go Slow”)
Start with 15mg of isolated CBG extract in the morning. CBG is moderately energizing, so daytime administration is ideal. If targeting gastrointestinal issues, consume 30 minutes before breakfast. Increase by 5mg weekly as required.
Entourage Synergies & Secondary Phyto-coupling
Medical Study Source Citations:
Current Clinical Drug Design (2021): CBG exhibits powerful anti-inflammatory effects in colon tissue parameters and stimulates cell-level repair without any cerebral side-effects.
